Skip to content
The Nexus
DossierENTITY

Puja Sapra

Coverage of Puja Sapra in the Nexus archive.

Earliest in view: Jul 23 · 12:00 UTCMost recent: Jul 23 · 12:00 UTC
Co-mentioned in this coverage
AstraZenecaorganization1AI-assisted designtopic1biologic medicinestopic1build-measure-learn looptopic1multi-specific biologicstopic1
Recent coverage
  • HEALTHJul 23 · 12:00 UTCMIT TECHNOLOGY REVIEW
    How AI helps scientists design the next generation of medicines

    AI is accelerating biologic drug development by narrowing molecular candidates and enabling faster timelines, with companies like AstraZeneca using AI to tackle previously untreatable diseases. Puja Sapra of AstraZeneca highlights AI's role in optimizing drug design and increasing R&D productivity.

Puja Sapra · Dossier · The Nexus